MagAssist Medical Continues Five-Year Streak as Jiangsu Potential Unicorn, Pioneering Multi-Organ Life Support Technologies

Recently, the Jiangsu New Quality Productivity Promotion Center released the evaluation results of Jiangsu Unicorn and Gazelle Enterprises for 2025.magAssistWith its continuous innovation and outstanding performance in the medical device field,Successfully selected for the "List of Jiangsu Province's Potential Unicorn Enterprises" for five consecutive years。

This continued recognition not only reflects the hard-core innovative strength of magAssist but also demonstrates the company’s deep alignment with the core criteria of a potential unicorn. As a hard-tech enterprise registered in Suzhou with independent legal person status, magAssist has, over the past eight years, fully demonstrated the potential of being a "pioneer in opening up new fields and creating new tracks" through its technological breakthroughs and industrialization achievements in the multi-organ life support sector. This award also highlights Jiangsu Province's high recognition of technology-driven enterprises.

Partial List of Potential Unicorn Companies in Jiangsu Province, 2025

As a provincial potential unicorn enterprise, magAssist has always focused on China's major clinical needs since its establishment. Relying on the mature medical industry system, excellent business environment, and abundant talent resources in Jiangsu Province, Suzhou City, and the High-Tech Zone, with the core model of "medical-engineering integration and joint research," through interdisciplinary integration and system integration technologies such as engineering science, medicine, and biomechanics, magAssist has deeply cultivated the development of a multi-organ life support platform and has become a leader in this field. Its core product portfolio not only fills several gaps in China but also showcases the strong capabilities of domestically produced medical equipment on the international stage.

• Total Artificial Heart with External Full Magnetic LevitationMoyoAssist®：As a core breakthrough achievement independently developed by magAssist, this product has received approval through the National Medical Products Administration (NMPA) Innovative Medical Device Special Review Process and was officially granted registration for market launch in April 2024. By February 2025, it achieved two further breakthroughs—expanding the ECMO application scope of the main unit to provide ventricular or cardiopulmonary support, while being included in the medical insurance programs of Jiangsu Province and Suzhou City. This progress not only breaks the technical monopoly of foreign products in this field and fills the gap in domestically produced equipment for heart failure treatment in China, but also allows advanced medical technology to move from "clinically available" to truly "patient accessible" through medical insurance inclusion, achieving deep integration between "technological self-reliance" and "improving people's well-being."

  
  

• Minimally Invasive Interventional Artificial HeartNyokAssist®：Set a global industry record — successively receiving the U.S. FDA "Breakthrough Device" designation and the approval of the National Medical Products Administration (NMPA) Innovative Medical Device Special Review Program, becoming the world’s first artificial heart product to obtain “dual innovation” certification in both China and the U.S. In August 2023, Academician Ge Junbo from Zhongshan Hospital Affiliated with Fudan University in Shanghai led the completion of the first clinical case using this product. Subsequent clinical trials further validated its superior performance: In high-risk PCI protection scenarios, NyokAssist® demonstrated quick and easy implantation, minimal trauma, and rapid patient recovery. All enrolled patients were successfully weaned off the device and discharged after recovery, offering heart failure patients a safer and innovative minimally invasive treatment option.

  
  

• New Generation PortableECMOSystemBreathMo®：As another innovative achievement by magAssist in the field of acute and critical life support, this system has not only wonSupported by the Special Fund Project for the Transformation of Scientific and Technological Achievements in Jiangsu Province, it made a real "debut" during the 2023 Hangzhou Asian Games — as advanced emergency equipment installed on a large 5G mobile emergency resuscitation unit. This large 5G emergency resuscitation unit establishes the world's first [1] "large bus + emergency + 5G" mobile emergency model, becoming a model for mobile emergency units and promoting regular deployment. It can be widely applied in scenarios such as accident sites, disaster relief sites, and security for large events. The ECMO system from magAssist, as the latest generation of emergency life-saving equipment, is deeply integrated into this model, reinforcing a "mobile defense line" to safeguard the lives and health of the masses.

  
  

Currently, magAssist has preliminarily completed the product pipeline layout "starting from heart failure and extending to multi-organ life support," achieving full coverage of non-endpoint treatment for heart failure, the widest range of indications, and multi-scenario and multi-age group coverage. It has become a benchmark for hard technology enterprises in Jiangsu Province in "tackling key core technologies and achieving industrialization." In the future, the company will continue to focus on overcoming key core technologies in the field of life support, injecting stronger momentum into accelerating the domestic substitution of medical devices and promoting China's high-level self-reliance and strength in medical technology.

Source: [1] Qian Chenfei. (2023, September 7). The world's first large-scale 5G mobile emergency resuscitation unit launched in Hangzhou. China News Service.

- END -